Method of treating lymphedema comprising administering VEGF-D

Details Method of treating lymphedema comprising administering VEGF-D Method of treating lymphedema comprising administering VEGF-D

2009-02-05

2010-11-09

Landsman, Robert (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07829536

ABSTRACT:
The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.

REFERENCES:
patent: 5002867 (1991-03-01), Macevicz
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5202231 (1993-04-01), Drmanac et al.
patent: 5521065 (1996-05-01), Whiteley et al.
patent: 5631237 (1997-05-01), Dzau et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5837832 (1998-11-01), Chee et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6107046 (2000-08-01), Alitalo et al.
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6171799 (2001-01-01), Skibbens et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6235713 (2001-05-01), Achen et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6331302 (2001-12-01), Bennett et al.
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6383484 (2002-05-01), Achen et al.
patent: 6403088 (2002-06-01), Alitalo et al.
patent: 6451764 (2002-09-01), Lee et al.
patent: 6576608 (2003-06-01), Lee et al.
patent: 6608182 (2003-08-01), Rosen et al.
patent: 6645933 (2003-11-01), Alitalo et al.
patent: 6673343 (2004-01-01), Bennett et al.
patent: 6689580 (2004-02-01), Achen et al.
patent: 6730489 (2004-05-01), Achen et al.
patent: 6730658 (2004-05-01), Alitalo et al.
patent: 6818220 (2004-11-01), Alitalo et al.
patent: 6824777 (2004-11-01), Alitalo et al.
patent: 6958147 (2005-10-01), Alitalo et al.
patent: 7097986 (2006-08-01), Achen et al.
patent: 7122654 (2006-10-01), Achen et al.
patent: 7125714 (2006-10-01), Alitalo et al.
patent: 7410639 (2008-08-01), Achen et al.
patent: 7423125 (2008-09-01), Alitalo et al.
patent: 2002/0120123 (2002-08-01), Rosen et al.
patent: 2002/0146420 (2002-10-01), Bennett et al.
patent: 2002/0151489 (2002-10-01), Gravereaux et al.
patent: 2002/0182683 (2002-12-01), Hu et al.
patent: 2003/0008357 (2003-01-01), Hu et al.
patent: 2003/0028007 (2003-02-01), Hu et al.
patent: 2003/0166873 (2003-09-01), Lee et al.
patent: 2003/0211988 (2003-11-01), Epstein
patent: 2003/0232437 (2003-12-01), Zhang et al.
patent: 2004/0147448 (2004-07-01), Alitalo et al.
patent: 2004/0175730 (2004-09-01), Achen et al.
patent: 2004/0208879 (2004-10-01), Alitalo et al.
patent: 2005/0256075 (2005-11-01), Alitalo et al.
patent: 2006/0177428 (2006-08-01), Achen et al.
patent: 2006/0177901 (2006-08-01), Alitalo et al.
patent: 2007/0298493 (2007-12-01), Achen et al.
patent: 2008/0058258 (2008-03-01), Achen et al.
patent: 2008/0070831 (2008-03-01), Achen et al.
patent: 2008/0145366 (2008-06-01), Achen et al.
patent: 2008/0241152 (2008-10-01), Alitalo et al.
patent: 2008/0241153 (2008-10-01), Alitalo et al.
patent: 2009/0087905 (2009-04-01), Achen et al.
patent: 2009/0104198 (2009-04-01), Alitalo et al.
patent: WO-96/39515 (1996-12-01), None
patent: WO-97/05250 (1997-02-01), None
patent: WO-98/07832 (1998-02-01), None
patent: WO-98/33917 (1998-08-01), None
patent: WO-99/46364 (1999-09-01), None
patent: WO-00/45835 (2000-08-01), None
patent: WO-01/51075 (2001-07-01), None
patent: WO-02/29087 (2002-04-01), None
patent: WO-02/83704 (2002-10-01), None
patent: WO-02/83849 (2002-10-01), None
Achen et al., Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4),Proc. Natl. Acad. Sci. USA, 95: 548-53 (1998).
Ahern, Biochemical, reagent kits offer scientists good return on investment, <www.thescientist.library.upenn.edu/yr1995/july/tools 950724.html>.
Akane et al., Direct dideoxy sequencing of genomic DNA by ligation-mediated PCR,Biotechniques, 16: 238-41 (1994).
Anderson et al., Human gene therapy,Nature, 392: 25-30 (1998).
Aprelikova et al., FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter,Cancer Res., 52: 746-8 (1992).
Barrowman, Gastrointestinal Lymphatics,Lymph Stasis: Pathophysiology, Diagnosis and Treatment, Chapter 9, CRC Press, Boca Raton, FL, pp. 211-31 (1991).
Boshart et al., a very strong enhancer Is located upstream of an immediate early gene of human cytomegalovirus,Cell, 41: 521-30 (1985).
Boultwood et al., Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q-syndrome: Delineation of the critical region on 5q and identification of a 5q- breakpoint,Genomics, 19: 425-32 (1994).
Browman et al., Comprehensive human genetic maps: Individual and sex-specific variation in recombination,Am. J. Hum. Genet., 63: 861-9 (1998).
Campbell-Beggs et al., Chyloabdomen in a neonatal foal,Veterinary Record, 137: 96-8 (1995).
Castenholz, Structure of initial and collecting lymphatic vessels,Lymph Stasis: Pathophysiology, Diagnosis, and Treatment, Chapter 2, CRC Press: Boca Raton, FL, pp. 15-42 (1991).
Crystal et al., Transfer of genes to humans: early lessons and obstacles to success,Science, 270: 404-10 (1995).
Dale, The inheritance of primary lymphoedema,J. Med. Genet., 22: 274-8 (1985).
Davis et al., Direct gene transfer into skeletal muscle in vivo: Factors affecting efficiency of transfer and stability of expression,Hum. Gene Ther., 4: 151-9 (1993).
Dignam et al., Balbiani ring 3 inChironomus tentansencodes a 185-kDa secretory protein which is synthesized throughout the fourth larval instar,Gene, 88: 133-40 (1990).
Ding et al., A single amino acid determines the immunostimulatory activity of interleukin 10,J. Exp. Med., 191: 213-24 (2000).
Douglas et al., Direct sequencing of double-stranded PCR products incorporating a chemiluminescent stection procedure,Biotechniques, 14: 824-8 (1993).
Drmanac et al., Accurate sequencing by hybridization for DNA diagnostics and individual genomics,Nat. Biotechnol., 16: 54-8 (1998).
Drmanac et al., DNA sequence determination by hybridization: A strategy for efficient large-scale sequencing,Science, 260: 1649-52 (1993).
Dumont et al., Cardiovascular failure in mouse embryos deficient in VEGF receptor-3,Science, 282: 946-9 (1998).
Evans et al., Mapping of primary congenital lymphedema to the 5q35.3 region,Am. J. Hum. Genet., 64: 547-55 (1999).
Ferrell et al., Hereditary lymphedema: evidence for linkage and genetic heterogeneity,Hum. Mol. Genetics, 7: 2073-8 (1998).
Fischer et al., DNA fragments differing by single base-pair substitutions are separated in denaturing gradient gels: Correspondence with melting theory,Proc. Natl. Acad. Sci, USA, 80: 1579-83 (1983).
Fournier et al., Mutation in tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor,Oncogene, 11: 921-31 (1995).
Fournier et al., Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling,Oncogene, 18: 507-14 (1999).
Fox et al., Angiogenic gene therapy,Circulation, 94: 3065-6 (1996).
Galland et al., Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene,Genomics, 13: 475-8 (1992).
Galland et al., The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor,Oncogene, 8: 1233-40 (1993).
Gene Characterization Kits, Stratagene Catalogue, pp. 39-40 (1988).
Genetic variants and strains of the laboratory mouse, 2nd ed., New York: Oxford University Press, p. 70 (1989).
Gnatenko et al., Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression in vascular cells,J. Investig. Med., 45: 87-98 (1997).
Greenlee et al., Developmental disorders of the lymphatic system,Lymphology, 26: 156-68 (1993).
Holmes et al., Hereditary late-onset lymphedema,Pediatrics61: 575-9 (1978).
Isner et al., Arterial gene therapy for restenosis,Hum. Gene Ther., 7: 989-1011 (1996).
Isner et al., Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease,Circulation, 91: 2687-92 (1995).
Jabs et al., A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis cell, 75: 443-50 (1993).
Jeltsch et al., Hyperplasia of lymphatic vessels in VEGF-C transgenic mice,Science, 276: 1423-5 (1997).
Joukov et al.,

Affiliated with

Also associated with

Rating

Method of treating lymphedema comprising administering VEGF-D does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating lymphedema comprising administering VEGF-D, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating lymphedema comprising administering VEGF-D will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4190182